Investment Update : West Fountain Parallel Fund invested in early biotech company Bryolgyx
In November 2018, West Fountain Global Fund LP ("West Fountain"), an offshore parallel fund of West Fountain Parallel Fund, completed an investment in biopharmaceutical company Bryolgyx, Inc. ("Bryolgyx").
Founded in December 2016, BryoLogyx is a biopharmaceutical company developing innovative cancer immunotherapy platforms and HIV therapies, relied on exclusive technologies from Professor Paul Wender, a renowned professor at Stanford University and a member of the American Academy of Sciences.
The company is currently working closely with National Cancer Institute (NCI) to develop combinatorial cancer therapies based on the company's product and holds more than four patents. The therapies in development based on Bryostatin 1 molecule are designed to enhance the efficacy of related therapies by affecting the expression of multiple proteins, particularly disease-related targets. It is a platform technology with significant scope for collaboration with existing and developing therapies in the marketplace in the areas of cancer and HIV treatment.